See more : PT Indah Prakasa Sentosa Tbk (INPS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Atossa Therapeutics, Inc. (ATOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atossa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bowen Fintech Plc (BWN.L) Income Statement Analysis – Financial Results
- PT Bank Rakyat Indonesia (Persero) Tbk (BKRKF) Income Statement Analysis – Financial Results
- Forian Inc. (FORA) Income Statement Analysis – Financial Results
- PT Semen Indonesia (Persero) Tbk (PSGTY) Income Statement Analysis – Financial Results
- 727 Communications, Inc. (SVNJ) Income Statement Analysis – Financial Results
Atossa Therapeutics, Inc. (ATOS)
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.76K | 525.95K | 632.56K | 481.84K | 1.50K | 0.00 | 0.00 |
Cost of Revenue | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 132.41K | 340.66K | 495.47K | 65.63K | 97.19K | 0.00 | 0.00 |
Gross Profit | -23.00K | -8.00K | -23.00K | -46.60K | -52.79K | -44.20K | -128.99K | -303.48K | -130.65K | 185.30K | 137.09K | 416.21K | -95.69K | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,431.91% | 35.23% | 21.67% | 86.38% | -6,379.33% | 0.00% | 0.00% |
Research & Development | 17.33M | 15.08M | 9.21M | 6.61M | 6.65M | 4.21M | 2.33M | 770.43K | 2.36M | 2.58M | 1.11M | 1.97K | 0.00 | 120.00K | 21.25K |
General & Administrative | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 8.85M | 8.63M | 8.56M | 5.02M | 3.17M | 882.16K | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 1.27M | 1.26M | 466.82K | 160.85K | 12.20K | 0.00 |
SG&A | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 10.27M | 9.90M | 9.82M | 5.49M | 3.33M | 894.36K | 101.61K |
Other Expenses | 0.00 | -146.00K | -85.00K | 50.80K | 25.65K | 29.30K | 154.00 | 718.97K | 0.00 | 2.01M | 0.00 | 0.00 | 0.00 | 63.64K | 0.00 |
Operating Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.63M | 12.48M | 10.92M | 5.49M | 3.33M | 1.08M | 122.86K |
Cost & Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.76M | 12.82M | 11.42M | 5.55M | 3.43M | 1.08M | 122.86K |
Interest Income | 4.34M | 877.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 260.00 | 295.00 | 1.22K | 4.91K | 455.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.82K | 0.00 | 0.00 | 15.77K | 360.00 | 12.04K | 17.99K | 9.14K | 0.00 |
Depreciation & Amortization | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 272.63K | 564.46K | 472.93K | 130.55K | 15.62K | 455.00 | 0.00 |
EBITDA | -31.35M | -27.68M | -20.50M | -14.56M | -17.21M | -11.39M | -7.80M | -6.37M | -12.49M | -9.35M | -10.31M | -4.94M | -3.41M | -1.09M | -122.86K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -710,262.91% | -2,336.62% | -1,630.11% | -1,024.66% | -227,243.60% | 0.00% | 0.00% |
Operating Income | -31.38M | -27.69M | -20.52M | -14.61M | -17.27M | -11.43M | -7.65M | -7.97M | -12.76M | -14.64M | -10.78M | -5.07M | -3.43M | -1.08M | -122.86K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,746.19% | -2,783.97% | -1,704.93% | -1,052.01% | -228,612.67% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.28M | 731.00K | -85.00K | -3.22M | 25.65K | 29.30K | -473.41K | 0.00 | 431.00 | -2.49M | -65.00 | -10.82K | -13.08K | -8.68K | 0.00 |
Income Before Tax | -30.09M | -26.96M | -20.61M | -17.83M | -17.24M | -11.40M | -8.12M | -6.37M | -12.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,721.67% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -731.00K | -213.56K | 3.27M | -119.07K | -29.30K | 742.46K | -1.76M | 3.00M | 2.35M | 65.00 | 10.82K | 13.08K | 250.00 | 0.00 |
Net Income | -30.09M | -26.23M | -20.61M | -21.10M | -17.24M | -11.40M | -8.12M | -6.37M | -15.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,491.64% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
EPS | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.96 | -2.42 |
EPS Diluted | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.58 | -2.42 |
Weighted Avg Shares Out | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 32.98K | 50.77K |
Weighted Avg Shares Out (Dil) | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 33.36K | 50.77K |
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
Atossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3Q
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Atossa Therapeutics adds experienced finance exec to board of directors
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
Source: https://incomestatements.info
Category: Stock Reports